Precision diagnostics Pathnostics offers rapid Guidance UTI testing with PCR sensitivity and P-AST antibiotic susceptibility, presenting a strong opportunity to partner with hospitals and health systems seeking faster, targeted antimicrobial therapy and reduced turnaround times for complex UTIs.

Infectious disease focus With a specialty in infectious disease and cancer diagnostics and a commitment to antibiotic stewardship, Pathnostics can be positioned for expanding collaborations with infection control, antimicrobial stewardship programs, and oncology support services within mid to large healthcare networks.

Strategic partnerships Past collaborations with Sunquest and Thermo Fisher show openness to integration and multi-lab networks; sales efforts can target labs and EMR/LIS integrations to extend order connectivity and broaden test adoption across networks.

Growth and scale Revenue in the tens of millions and a growth-oriented investor spotlight suggest opportunities to explore value-based partnerships, targeted pilots, and additional funding-friendly trials with health systems seeking measurable improvements in UTI management and antibiotic stewardship outcomes.

Innovation ecosystem Pathnostics combines advanced molecular testing with easy-to-read reports and rapid results; positioning could emphasize integration potential with existing diagnostic platforms, cross-selling to cancer diagnostics, and leveraging their ELK/Snowflake/Azure tech stack for data-driven outcomes in networked laboratories.